BioRestorative Therapies (BRTX) Non-Current Deferred Tax Liability (2016 - 2020)
BioRestorative Therapies' (BRTX) quarterly Non-Current Deferred Tax Liability came in at $30000.0 in Q4 2020, up 15.38% YoY from $26000.0 in Q1 2020, and up 15.38% on a QoQ basis from $26000.0 in Q4 2019.
BioRestorative Therapies (BRTX) Non-Current Deferred Tax Liability (2016 - 2020) Analysis & Trends
BioRestorative Therapies (BRTX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $30000.0 in Q4 2020.
- Quarterly Non-Current Deferred Tax Liability rose 15.38% year-over-year to $30000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $30000.0 (up 15.38% YoY) and the FY2020 annual result came in at $30000.0, up 15.38% from the prior year.
- Non-Current Deferred Tax Liability grew to $30000.0 in Q4 2020, from $26000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $30000.0 in Q4 2020 to a low of -$2000.0 in Q4 2018.
- A 5-year average of $17600.0 and a median of $18000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability plunged 112.5% — and 2019, when it surged 1400.0%.
- Tracing BRTX's Non-Current Deferred Tax Liability over 5 years: stood at $18000.0 in 2016, then retreated by 11.11% to $16000.0 in 2017, then sank by 112.5% to -$2000.0 in 2018, then surged by 1400.0% to $26000.0 in 2019, then rose by 15.38% to $30000.0 in 2020.
- The last three Non-Current Deferred Tax Liability figures came in at $30000.0 (Q4 2020), $26000.0 (Q4 2019), and -$2000.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 30,000.00 |
| Dec 31, 2020 | 30,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Dec 31, 2018 | -2,000.00 |
| Dec 31, 2018 | -2,000.00 |
| Dec 31, 2017 | 16,000.00 |
| Dec 31, 2017 | 16,000.00 |
| Dec 31, 2016 | 18,000.00 |
| Dec 31, 2016 | 18,000.00 |